GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced ALK-positive non-small cell lung cancer. In the trial, the confirmed overall response rate was 49% (33/67) in patients previously treated with alectinib only.
GSK · GSK plc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
GSK plans to deliver 1.9 billion of costs by 29 through restructuring across its value chain, with most of the savings reinvested in R&D. It also says it will not slow down on BD.
GSK plc reports that Hal Barron, James Ford and Maya Martinez-Davis acquired American Depositary Shares via dividend reinvestment in executive savings plan accounts on 2026-11-13 at $50.4500.
GSK plc announced CHMP recommended updating the Bexsero label for a single booster dose in individuals aged 10 years and older vaccinated at least two years earlier. Men-B-096 met its primary endpoint, showing immune memory from infant vaccination can be boosted up to 19 years later.
GSK plc disclosed that Lynn Baxter and other executives or a PCA acquired ordinary shares under the Share Reward Plan at £19.3453 on 2026-11-10. Maya Martinez-Davis acquired 9.264 notional ADS at $51.5400 on 2026-11-09.
GSK accelerated six pivotal phase three starts for its long-acting TSLP, Falcora Kibart, across asthma, nasal polyps and COPD, a very material acceleration of nine months. Management said there is absolutely no uncertainty that the drug is a twice yearly dose medicine, and the data will be shared next year.
GSK plc announced provisional dividend dates for 2027, including Q1 results on Wednesday 28 April 2027 and payment on Thursday 15 July 2027, and Q4 results on Wednesday 2 February 2028 and payment on Thursday 13 April 2028.
GSK plc reported 4,045,439,182 total voting rights as at 31 October 2026, based on 4,316,320,246 issued ordinary shares and 270,881,064 treasury shares.
GSK reported sales up 5% to £8.9 billion and core operating profit up 5%, with core earnings per share up 1%. It reconfirmed 2026 guidance, with sales expected in the upper half of the range. Charges under the Accelerate Growth programme are now expected to be up to £1bn in 2026.
GSK reported Q3 sales of £8.9 billion, up 5% at CER, with core operating profit up 5%. It reaffirmed 2026 guidance for turnover growth of 3% to 5% and core operating profit growth of 7% to 9%.
GSK’s ARTEMIS-011 trial found Ris-Rez reduced disease progression or death risk by 67% versus chemotherapy in relapsed osteosarcoma, with median progression-free survival of 5.5 months versus 1.4 months; Hansoh plans a China regulatory submission.
GSK plc reported that Maya Martinez-Davis acquired notional American Depositary Shares in her GSK Executive Supplemental Savings Plan account on 2026-10-22, at $51.2100 for volume 9.324, on the New York Stock Exchange (XNYS).
GSK plc reported interim AZUR-1 results: 76% of evaluable patients achieved complete response to Jemperli monotherapy; independent review showed 47% achieved sustained cCR12, with no recurrences among responders after median follow-up of more than two years.
GSK reported positive phase Ib BEHOLD-1 results for Mo-Rez in platinum-resistant ovarian cancer: 62% confirmed objective response rate, 12.2-month median duration of response and 11.1-month median progression-free survival; five pivotal phase III studies are underway.
GSK plc announced that the FDA approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B, with phase III trials showing a 19% functional cure rate after six-month treatment versus less than 1% for standard care alone.
GSK announced the US FDA approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer under the accelerated approval pathway. Approval was based on phase II AZUR-1 trial data.
GSK presented first global data for its B7-H3-targeted ADC Ris-Rez in relapsed extensive-stage small cell lung cancer, showing a 61% confirmed ORR at 8 mg/kg (n=11/18; 95% CI: 35.7-82.7) versus 32% at 6 mg/kg, supporting its global phase III EMBOLD SCLC-301 study.
On 2026-10-13, GSK plc executives James Ford, Maya Martinez-Davis and Shobie Ramakrishnan acquired American Depositary Shares through dividend reinvestment, purchasing 326.441, 351.842 and 724.875 shares respectively at $46.9482 each on the New York Stock Exchange (XNYS).
GSK plc reported increases in executives’ notional interests from dividend reinvestment on 2026-10-12, involving Ordinary Shares and American Depositary Shares.
GSK plc reported dividend-reinvestment acquisitions by executives and directors, including ordinary shares at £17.5904 on 2026-10-08 and American Depositary Shares at $46.5883 on 2026-10-09.
GSK plc reported PDMR and closely associated person acquisitions through dividend reinvestment and Share Reward Plan awards, plus a notional ADS purchase, on 2026-10-07, 2026-10-08 and 2026-10-09.
GSK plc announced that Wendy Becker, an independent Non-Executive Director, was appointed as a Non-Executive Director of Tesco PLC effective 1 November 2026.
GSK plc notified that 19,352 ordinary shares of 31¼ pence each were admitted to the London Stock Exchange – Main Market, bringing the total to 4,316,311,662 for 7 August 2026 – 2 October 2026.
GSK plc reported 4,045,430,485 total voting rights as at 30 September 2026, based on 4,316,311,549 issued Ordinary Shares, of which 270,881,064 were held in Treasury.
GSK plc disclosed that Maya Martinez-Davis acquired 9.414 notional American Depositary Shares on 2026-09-22, at $50.7200 per ADS, through her Executive Supplemental Savings Plan on the New York Stock Exchange.
GSK expects margin to remain stable or improve through the HIV patent cliff, using 1.9 billion of savings to fund seven major assets across about 18 indications while supporting specialty growth and new launches.
GSK plc disclosed director purchases of Ordinary Shares and ADS on 2026-09-18.